Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). DuoGenic StemCells's share price for the quarter that ended in Dec. 2025 was NT$18.45. DuoGenic StemCells's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 35.55 Mil. Therefore, DuoGenic StemCells's market cap for the quarter that ended in Dec. 2025 was NT$655.95 Mil.
DuoGenic StemCells's quarterly market cap
declined
from Dec. 2024 (NT$705.77 Mil) to Jun. 2025 (NT$326.39 Mil) but then
increased
from Jun. 2025 (NT$326.39 Mil) to Dec. 2025 (NT$655.95 Mil).
DuoGenic StemCells's annual market cap
declined
from Dec. 2023 (NT$1,099.91 Mil) to Dec. 2024 (NT$705.77 Mil) and
declined
from Dec. 2024 (NT$705.77 Mil) to Dec. 2025 (NT$655.95 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. DuoGenic StemCells's Enterprise Value for Today is NT$448.98 Mil.
DuoGenic StemCells (ROCO:7607) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
DuoGenic StemCells Market Cap Related Terms
DuoGenic StemCells Market Cap Historical Data
* Premium members only.
The historical data trend for DuoGenic StemCells's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:7607 vs VRTX, REGN, ALNY: Market Cap Comparison
For the Biotechnology subindustry, DuoGenic StemCells's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DuoGenic StemCells Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, DuoGenic StemCells's Market Cap distribution charts can be found below:
* The bar in red indicates where DuoGenic StemCells's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
DuoGenic StemCells's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DuoGenic StemCells (ROCO:7607) has a Market Cap of NT$476.49 Mil as of Jul. 26, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on DuoGenic StemCells and its competitors. According to the industry distribution chart, DuoGenic StemCells ranks #1146 out of 1422 companies in the Biotechnology industry, placing it in the top 80.6%.
Is DuoGenic StemCells' Market Cap too high?
DuoGenic StemCells' current Market Cap is NT$476.49 Mil. Based on the distribution chart, DuoGenic StemCells ranks #1146 out of 1422 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, DuoGenic StemCells has a GF Score™ of 25/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does DuoGenic StemCells' Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, DuoGenic StemCells ranks #1146 out of 1422 companies for Market Cap. This places DuoGenic StemCells in the lower half of its industry. The industry median Market Cap is 110.94. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 110.94, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on DuoGenic StemCells and its competitors. For the Biotechnology industry, the median Market Cap is 110.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DuoGenic StemCells's current Market Cap is NT$476.49 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DuoGenic StemCells stock overvalued right now?
Based on GuruFocus' analysis, DuoGenic StemCells (ROCO:7607) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$51.22, compared to a current price of NT$13.00 — trading 74.6% below its estimated fair value. The current Market Cap is NT$476.49 Mil. DuoGenic StemCells' overall GF Score™ is 25/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For DuoGenic StemCells (ROCO:7607), the current Market Cap is NT$476.49 Mil as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DuoGenic StemCells (ROCO:7607) Overvalued in 2026?
Based on GuruFocus' analysis, DuoGenic StemCells stock appears to be undervalued.
The current stock price of NT$13.00 is trading 74.6% below its estimated GF Value™ of NT$51.22.
GuruFocus considers DuoGenic StemCells to be Significantly Undervalued.
Key valuation signals for ROCO:7607:
Market Cap: NT$476.49 Mil
GF Value™: NT$51.22 vs. price of NT$13.00 (74.6% below fair value)
No single metric tells the full story. See the ROCO:7607 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DuoGenic StemCells Corp is a company having a team of passionate researchers focused on stem cell cultivation. Their products are intended for research use and can be upgraded for clinical applications. It also develops blood cell therapy programs, using the isolation and purification of blood mononuclear cells to remove granule cells that promote inflammation, and conducts clinical trials on various degenerative diseases to provide a convenient and simple new option for cell therapy.
25GF Score
Get the complete analysis for ROCO:7607
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7607 has been successfully added to your 
